Clinical trials: T2DM (Type 2 Diabetes Mellitus)
Type 2 Diabetes Mellitus
A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312)
The purpose of this study is to examine the safety and tolerability of sitagliptin 100 mg/simvastatin 40 mg FDC (MK-0431D) in Vietnamese participants with type 2 diabetes mellitus with inadequate glycemic control on metformin.
- Trial name
- NCT01702298
- Testing
- Sitagliptin 100 mg/simvastatin 40 mg FDC, Metformin
- Volunteers
- 42 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes
Description of the real-life treatment of adult patients with type-2 diabetes mellitus (T2DM) receiving Empagliflozin, comparing the characteristics of patients starting Empagliflozin in three time intervals
- Trial name
- EDCOS (NCT04098575)
- Testing
- Empagliflozin
- Where
- Germany
- Volunteers
- 9,571 people
- Sponsor
- Boehringer Ingelheim
Healthy Volunteers, Diabetes Mellitus, Type 2
A Research Study to Evaluate the Safety of NNC1679-0001 When Given to Healthy Participants and Participants With T2DM
This study is testing a new medicine that might help treat people with type 2 diabetes. The purpose of the study is to see if the new study medicine is safe and how well is tolerated by the body.
- Trial name
- NCT07570992
- Testing
- NNC1679-0001
- Where
- Austria
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM Patients
GLP-1 receptor agonists (GLP-1 RA) is group of antidiabetic agents very effective in lowering the plasma glucose concentration in T2DM patients .
- Trial name
- NCT04135287
- Testing
- GLP-1 receptor agonist
- Where
- Kuwait
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- Dasman Diabetes Institute
Diabetes Mellitus, PreDiabetes
Effect of Low-Calorie Diet and Lifestyle Intervention on Reversal of T2DM
An increase in body fat, even when within the normal BMI range is one of the essential drivers of T2DM in Asian Indians. In this context, the relationship between excess hepatic fat and pancreatic fat appears to be necessary.
- Conditions
- Diabetes Mellitus, PreDiabetes, Diet Habit
- Trial name
- CURE-DM (NCT05925946)
- Testing
- CURE-DM
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Diabetes Foundation, India
Type 2 Diabetes Mellitus, Obese
Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes
The purpose of this study is to evaluate the safety, tolerability, and efficacy of ISIS-PTP1BRx + oral antidiabetic drug/s (metformin and/or sulfonylurea) versus placebo + oral antidiabetic drug/s.
- Trial name
- NCT01918865
- Testing
- ISIS-PTP1BRx, daily OAD (metformin and/or sulfonylurea)
- Where
- 21 sites in Argentina, Canada and 1 more
- Volunteers
- 92 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Diabetes
CSII Pilot in Adolescents With Type 2 Diabetes
This feasibility pilot is intended to understand whether adolescents with Type 2 Diabetes (2DM) can be transitioned to a continuous subcutaneous insulin injection (CSII) and if so, assess whether CSII is a feasible treatment…
- Trial name
- NCT02748122
- Testing
- MMT 723
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- NYU Langone Health
Nocturnal Hypertension, T2DM (Type 2 Diabetes Mellitus)
SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)
To explore the beneficial effects of 'empagliflozin + ARB' in comparison with 'placebo + ARB' on the reduction of nocturnal blood pressure in T2DM with hypertension
- Trial name
- NCT03050229
- Testing
- Empagliflozin
- Where
- 12 sites in Japan
- Volunteers
- 174 people
- Sponsor
- Jichi Medical University
Type 2 Diabetes
CGM Evaluation of Glucose Excursions in Basal Insulin Treated T2DM at Fasting Glucose Target
This is a trial to determine if patients who are well controlled and on basal insulin are treated with excessive basal dose.
- Trial name
- NCT01548222
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Diabetes Care Center
Metabolic Syndrome, Diabete Type 2
Metformin Versus Vildagliptin in Reducing Risk of Metabolic Syndrome Complications Progression
Several crosssectional and prospective studies have shown that metabolic syndrome and its related components are associated with both prevalent and incident CKD .
- Conditions
- Metabolic Syndrome, Diabete Type 2, Kidney Insufficiency
- Trial name
- NCT04485845
- Testing
- Vildagliptin, Captopril Tablets, MetFORMIN 500 Mg Oral Tablet
- Where
- Egypt
- Volunteers
- 39 people
- Sponsor
- Cairo University
Diabetes Mellitus, Type 2
Lifestyle and Glucose Lowering Medication in T2DM
This study evaluates the effect of a lifestyle intervention maintenance of glycemic control while reducing glucose lowering drugs in patients with type 2 diabetes mellitus.
- Trial name
- NCT02417012
- Testing
- U-TURN, Standard care
- Where
- Denmark
- Volunteers
- 97 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
T2DM (Type 2 Diabetes Mellitus)
A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin
This study is a multicenter, randomized, double-blind, placebo and active-controlled, dose-finding phase 2 study aimed to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of SYH2069 Injection in…
- Trial name
- NCT07796477
- Testing
- SYH2069 Injection (group 1), SYH2069 Injection (group 2), SYH2069 Injection (group 3)
- Where
- China
- Volunteers
- 240 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus (T2DM)
A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM
To evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-KHK and to evaluate the safety, tolerability, efficacy, PK and PD of multiple doses of KHK.
- Trial name
- NCT05761301
- Testing
- ALN-KHK
- Where
- 15 sites in United States, Canada
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Diabetes Mellitus, Type 2, Antioxidative Stress
Dietary Antioxidants and Thiol Disulfide Homeostasis in T2DM
This observational study was planned to determine the relationship between dietary antioxidant intake and thiol disulfide homeostasis of individuals with type 2 diabetes.
- Trial name
- NCT05688631
- Testing
- Dietary antioxidant intake
- Where
- Turkey (Türkiye)
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Ankara Yildirim Beyazıt University
Diabetes Mellitus, Type 2
The Role of Endogenous Glucagon-like Peptide 1 (GLP-1) in Type 2 Diabetes Mellitus (T2DM)
The purpose of the study is to determine the contribution of endogenous Glucagon-like peptide 1 (GLP-1) to the postprandial secretion of insulin and glucagon and the incretin effect in healthy subjects and patients with type 2…
- Trial name
- DFG_5 (NCT01449019)
- Testing
- exendin(9-39)amide, saline, duodenal meal
- Where
- 2 sites in Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Ludwig-Maximilians - University of Munich
Type 2 Diabetes, Obese Diabetics
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity
This study explores the long-term effects of dapagliflozin and empagliflozin on CYP8B1 gene expression and a range of metabolic, oxidative, and inflammatory biomarkers in obese patients with Type 2 Diabetes Mellitus (T2DM).
- Conditions
- Type 2 Diabetes, Obese Diabetics, Obese Patients (BMI ≥ 30 kg/m²)
- Trial name
- CYP8B1-SGLT2-T (NCT07120828)
- Testing
- Empagliflozin (oral), Dapagliflozin (DAPA), Metfomin
- Where
- Iraq
- Volunteers
- 260 people
- Sponsor
- Erbil Polytechnic University
Type 2 Diabetes Mellitus
An Observational Study to Evaluate Cardiovascular Outcomes of T2DM PatientsTreated With Gemigliptin
The primary objective of the study is to investigate cardiovascular safety of gemigliptin by evaluating the time until patients report with major adverse cardiovascular events (MACE) in T2DM patients treated with gemigliptin.
- Trial name
- NCT02290301
- Testing
- gemigliptin
- Where
- South Korea
- Volunteers
- 5,180 people
- Sponsor
- LG Life Sciences
Bioequivalence, Fixed Dose Combination Tablets
A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects
This is a bioequivalence study to compare 2 fixed-dose combination tablets of dapagliflozin/metformin XR manufactured at 2 different plants in healthy subjects under fasting and fed conditions
- Conditions
- Bioequivalence, Fixed Dose Combination Tablets, Healthy Male and Female Subjects
- Trial name
- NCT02637037
- Testing
- dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon), dapagliflozin/metformin XR 5/500 mg reference drug (Humacao), dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus (T2DM)
Helping Adults With Type 2 Diabetes Use Their Health Data for Healthy Diabetes Self-Management
Day-to-day self-management by adults with type 2 diabetes, including glucose monitoring, taking medications, and healthy habits, is essential to avoid diabetes complications, yet, despite the rapidly expanding availability of…
- Trial name
- MPowerHub (NCT06848361)
- Testing
- MPowerHub, Continuous Glucose Monitor (CGM), Activity Monitor
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Ann-Marie Rosland
Type 2 Diabetes Mellitus (T2DM)
Diabetes Management for Primary Healthcare Centers.
The purpose of this study, "Integrating diabetes care into Primary Healthcare Centers (PHCs) in Abuja, Nigeria: a pilot study," is to screen, diagnose, treat, and educate diabetes patients in two selected PHCs in Abuja.
- Trial name
- DM4PHC-pilot (NCT06907472)
- Testing
- Protocol-based treatment
- Where
- 2 sites in Nigeria
- Volunteers
- 106 people
- Sponsor
- University of Abuja